COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

FDA Issues Safety Communication Warning of Potential False Negatives with Curative SARS-Cov-2 Test

FDA maze of regulations
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

Curative SARS-Cov-2 diagnosis test providing high number of false negatives, FDA warns

The US Food and Drug Administration (FDA) released a safety communication Jan. 4, 2021, alerting patients and healthcare providers of “the risk of false results, particularly false negative results, with the Curative SARS-Cov-2 test.”

This new year safety communication does not address the background of how the increased number of false-negative results were discovered, or the changes in sensitivity, that healthcare providers should expect with this test. It is also notable that the FDA has not rescinded or revised the EUA that the Curative SARS-Cov-2 test received.

With the safety communication, the FDA provided information about how to reduce false positives when using the test. “To reduce the risk of false negative results, it is important to perform the test in accordance with its authorization and as described in the authorized labeling, e.g., the Fact Sheet for Healthcare Providers,” states the FDA communication. “When the test is not performed in accordance with its authorization or as described in the authorized labeling, there is a greater risk that the results of the test may not be accurate.”

The FDA does not have any information on whether these false negatives are related to the way the test is typically performed or if the test itself is the underlying causative factor. The full recommendations given by the FDA may be reviewed here.

Related Resources:

COVID-19 TESTING DATA

Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.

Sincerely,

Robert L. Michel
President, Founder
The Dark Intelligence Group